Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
6/2/24 | Bristol Myers Squibb (BMY) | Opdivo for Colorectal Cancer (CRC) | Subscribers Only | Subscribers Only | Subscribers Only |
6/1/24 | Roche (RHHBY) | Inavolisib for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/1/24 | Eli Lilly (LLY) | Verzenio for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
6/1/24 | Eli Lilly (LLY) | Olomorasib for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
6/1/24 | Jazz Pharmaceuticals (JAZZ) | Zanidatamab for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/19/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/09/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/18/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |